GGrantIndex
← Leaderboards

Allan J. Walkey

Boston University Medical Campus

$9,287,275
Attributed
$10,444,985
Total exposure
6
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.9M · FY201225
$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,444,985 · 6

By mechanism

R01$9,463,687 · 4
K01$741,665 · 1
R21$239,633 · 1

Top collaborators

Most similar at Boston University Medical Campus

Same institution · by research overlap

Others in their field

Top investigators on “Risk Factors

Research focus

Risk FactorsFutureInnovationHospitalizationHospitalsCritical IllnessSepsisCollaborationsAffectBasePatternUnited StatesCardiovascular SystemVariantElectronic Health RecordCharacteristicsBenefits And RisksResponseCessation Of LifeStrokeComorbidityAtrial FibrillationAmericanHeart Failure

Grant awards (23)

Informing best practices for evaluation and treatment of myocardial injury during sepsis$691,782
R01 · FY2025 · HL · contact PI
Informing best practices for evaluation and treatment of myocardial injury during sepsis$707,275
R01 · FY2024 · HL · contact PI
Informing best practices for evaluation and treatment of myocardial injury during sepsis$757,337
R01 · FY2023 · HL · contact PI
Evaluating Routine Opioid Use during Acute Respiratory Failure$528,084
R01 · FY2023 · HL · contact PI
Evaluating Routine Opioid Use during Acute Respiratory Failure$14,843
R01 · FY2023 · HL · contact PI
Evaluating Routine Opioid Use during Acute Respiratory Failure$541,739
R01 · FY2022 · HL · contact PI
Targeting cardiovascular events to improve patient outcomes after sepsis$668,389
R01 · FY2021 · HL · contact PI
Evaluating Routine Opioid Use during Acute Respiratory Failure$568,726
R01 · FY2021 · HL · contact PI
Targeting cardiovascular events to improve patient outcomes after sepsis$710,585
R01 · FY2020 · HL · contact PI
Evaluating Routine Opioid Use during Acute Respiratory Failure$662,029
R01 · FY2020 · HL · contact PI
Automated detection and prediction of atrial fibrillation during sepsis$535,600
R01 · FY2020 · HL · contact PI
Targeting cardiovascular events to improve patient outcomes after sepsis$701,112
R01 · FY2019 · HL · contact PI
Automated detection and prediction of atrial fibrillation during sepsis$535,600
R01 · FY2019 · HL · contact PI
Targeting cardiovascular events to improve patient outcomes after sepsis$744,234
R01 · FY2018 · HL · contact PI
Automated detection and prediction of atrial fibrillation during sepsis$551,823
R01 · FY2018 · HL · contact PI
Automated detection and prediction of atrial fibrillation during sepsis$544,529
R01 · FY2017 · HL · contact PI
Atrial Fibrillation in Sepsis: Patient Outcomes and Provider Practice Patterns$169,560
K01 · FY2017 · HL · contact PI
Atrial Fibrillation in Sepsis: Patient Outcomes and Provider Practice Patterns$169,560
K01 · FY2016 · HL · contact PI
Atrial Fibrillation in Sepsis: Patient Outcomes and Provider Practice Patterns$134,298
K01 · FY2015 · HL · contact PI
Atrial Fibrillation in Sepsis: Patient Outcomes and Provider Practice Patterns$134,298
K01 · FY2014 · HL · contact PI
Atrial Fibrillation in Sepsis: Patient Outcomes and Provider Practice Patterns$133,949
K01 · FY2013 · HL · contact PI
Adiponectin in Acute Lung Injury$116,882
R21 · FY2013 · HL · contact PI
Adiponectin in Acute Lung Injury$122,751
R21 · FY2012 · HL · contact PI